Search

Efanesoctocog alfa

Efanesoctocog alfa (BIVV001) is a recombinant factor VIII (FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and on-demand treatment and control of bleeding … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand

Pemetrexed

Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.[A253907]

Depemokimab

[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

Lenograstim

Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

Lumiracoxib

Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

Baxdrostat

On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia due to non-selective

Potassium acetate

Tibolone

Tibolone has been to have anti-resorptive effects on bone [L1874]. … Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874].

Melphalan

[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.

Moxidectin

Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23.